Table 3.
General/Common RF | HPI-Induced Diseases and Disorders |
Advanced age | Anemia, iron deficiency |
Menopause/male hypogonadism | Vitamin B12 deficiency |
Body mass loss | Immune thrombocytopenia |
Low BMD | Chronic/atrophic gastritis |
Previous fragility fracture | PUD |
History of falls | Gastric malignancy |
Family history of OP/OFs | HPI- associated chronic diseases and disorders |
Ethnicity (Caucasian and Asian vs. black populations) | Cardiovascular diseases (CAD, CHF, AF, hypertension) |
Impaired balance, gait and mobility, need of assistive device * | Hemodynamic instability (orthostatic and/or postprandial hypotension, dizziness) # |
Low physical activity/immobilization | Cerebrovascular diseases (stroke, TIA) |
Low body mass index | Neurodegenerative diseases (dementia, Parkinson’s disease) |
Hemodynamic instability (orthostatic and/or postprandial hypotension, dizziness) # | COPD |
Visual impairment | CKD |
Vitamin D deficiency/insufficiency | Diabetes mellitus |
Vitamin K deficiency | Metabolic syndrome |
Hyperparathyroidism | CLD |
Urinary incontinence # | Depression, anxiety |
Low calcium intake | Rheumatologic diseases |
Fear of falling # | Eye diseases (open-angle glaucoma, neuromyelitis optica) |
Prolonged use of certain medications | Gut dysbiosis |
Corticosteroids, antidepressants (especially, SSRIs, SSNRIs), opioids, anxiolytics, hypnotics, sedatives (benzodiazepines), antiparkinsonian (dopaminergic) medications, antipsychotics, antiepileptics, glitazones, antiarrhythmics, PPIs, thyroxine, aromatase inhibitors, gonadotropin releasing hormone antagonists, immunosuppressive agents, polypharmacy | Malignant tumors (breast, lung, colorectal, prostate cancers) |
Environmental, lifestyle and socio-economic RF | |
Cigarette smoking, excess alcohol consumption, diet, urbanization, poor sanitation conditions, air pollution. |
Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; PPI, proton pump inhibitor; PUD, peptic ulcer disease; SSRI, selective serotonin reuptake inhibitors; SSNRI, selective serotonin-norepinephrine reuptake inhibitors; TIA, transient ischemic attack; # Risk factor for falls (not for OP); * although need for an assistive device indicates presence of conditions predisposing to falls, its appropriate use may actually decrease fall risk. Notes: Recent genetic studies have challenged some long-assumed risk factors for OP/OF. Mendelian randomization analyses identified BMD [413,635,636,637], serum estradiol concentrations (in men) [638] and cigarette smoking [639] as causal risk factors for OP/OFs, whereas genetic predisposition to lower levels of vitamin D and milk calcium intake [635,636,639,640], serum testosterone [638] and inflammation markers [641,642], as well as early menopause; late puberty, chronic (including CVD, DM and IBD) [413,414,643] and neuropsychiatric diseases (Alzheimer’s disease, schizophrenia and bipolar disorder) [644], alcohol consumption [645] and alcohol dependence [639] did not show causal effects on BMD and fracture risk. The genetic studies overcome many limitations of the previous observational studies but also contain potential bias; “the Mendelian randomization study design cannot be used to assess whether complications or treatment of those diseases influence fracture risk” [636].